| CD90 Expression on human primary cells and elimination of contaminating fibroblasts from cell cultures. | |
| | |
MedLine Citation:
|
PMID: 19296231 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Cluster Differentiation 90 (CD90) is a cell surface glycoprotein originally identified on mouse thymocytes. Although CD90 has been identified on a variety of stem cells and at varying levels in non-lymphoid tissues such as on fibroblasts, brain cells, and activated endothelial cells, the knowledge about the levels of CD90 expression on different cell types, including human primary cells, is limited. The goal of this study was to identify CD90 as a human primary cell biomarker and to develop an efficient and reliable method for eliminating unwanted or contaminating fibroblasts from human primary cell cultures suitable for research pursuant to cell based therapy technologies. |
| | |
Authors:
|
Lynn Kisselbach; Michael Merges; Alexis Bossie; Ann Boyd |
Publication Detail:
|
Type: Journal Article Date: 2009-03-19 |
Journal Detail:
|
Title: Cytotechnology Volume: 59 ISSN: 0920-9069 ISO Abbreviation: Cytotechnology Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2009-05-05 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8807027 Medline TA: Cytotechnology Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 31-44 Citation Subset: B |
Affiliation:
|
Department of Cell Therapy, Lonza Walkersville, Inc., Walkersville, MD, 21793, USA, lynn.kisselbach@lonza.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Monitoring deterioration of vegetation cover in the vicinity of smelting industry, using statistical...
Next Document: Pharmacokinetics, urinary excretion and plasma protein binding of danofloxacin following intravenous...